1. Home
  2. GF vs GALT Comparison

GF vs GALT Comparison

Compare GF & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GF
  • GALT
  • Stock Information
  • Founded
  • GF 1990
  • GALT 2000
  • Country
  • GF Germany
  • GALT United States
  • Employees
  • GF N/A
  • GALT N/A
  • Industry
  • GF Investment Managers
  • GALT Biotechnology: Pharmaceutical Preparations
  • Sector
  • GF Finance
  • GALT Health Care
  • Exchange
  • GF Nasdaq
  • GALT Nasdaq
  • Market Cap
  • GF 138.1M
  • GALT 147.8M
  • IPO Year
  • GF N/A
  • GALT N/A
  • Fundamental
  • Price
  • GF $7.93
  • GALT $1.04
  • Analyst Decision
  • GF
  • GALT Strong Buy
  • Analyst Count
  • GF 0
  • GALT 1
  • Target Price
  • GF N/A
  • GALT $11.00
  • AVG Volume (30 Days)
  • GF 28.1K
  • GALT 1.1M
  • Earning Date
  • GF 01-01-0001
  • GALT 11-13-2024
  • Dividend Yield
  • GF 0.82%
  • GALT N/A
  • EPS Growth
  • GF N/A
  • GALT N/A
  • EPS
  • GF N/A
  • GALT N/A
  • Revenue
  • GF N/A
  • GALT N/A
  • Revenue This Year
  • GF N/A
  • GALT N/A
  • Revenue Next Year
  • GF N/A
  • GALT N/A
  • P/E Ratio
  • GF N/A
  • GALT N/A
  • Revenue Growth
  • GF N/A
  • GALT N/A
  • 52 Week Low
  • GF $7.38
  • GALT $0.73
  • 52 Week High
  • GF $9.41
  • GALT $4.27
  • Technical
  • Relative Strength Index (RSI)
  • GF 32.28
  • GALT 20.80
  • Support Level
  • GF $8.09
  • GALT $1.80
  • Resistance Level
  • GF $8.44
  • GALT $2.36
  • Average True Range (ATR)
  • GF 0.10
  • GALT 0.27
  • MACD
  • GF -0.03
  • GALT -0.08
  • Stochastic Oscillator
  • GF 7.80
  • GALT 15.07

About GF New Germany Fund Inc. (The)

NEW GERMANY FUND INC is a United States-based non-diversified, closed-end management investment company. As the investment objective, the fund seeks long-term capital appreciation through investment in middle-market German equities. The fund's portfolio of investment includes investments in different sectors such as the industrials, information technology, material, consumer discretionary, Communication Services, Financials, Consumer Staples, Real Estate, Utilities, Healthcare, Energy, and others. Its portfolio is geographically diversified across the Netherlands, Germany, and Luxembourg.

About GALT Galectin Therapeutics Inc.

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

Share on Social Networks: